Difficulties of Morbid Obesity in Gynaecological Health Management

Albert Opal*

Department of Food Science and Nutrition, Sultan Qaboos University, Oman

Abstract

Morbid obesity presents signiýcant challenges in gynecological health management, impacting diagnosis, treatment, and overall patient care. This abstract reviews the multifaceted di culties encountered by healthcare providers when managing patients with morbid obesity in a gynecological context. Obese patients often experience a range of complications, including reproductive issues, increased risk of comorbidities, and limitations in diagnostic procedures. The presence of excess adipose tissue can a ect hormone levels, leading to conditions such as polycystic ovary syndrome (PCOS) and irregular menstrual cycles. Additionally, surgical interventions may be more complex due to increased risks of anesthesia complications and di culties in accessing the surgical ýeld. Healthcare providers may also face barriers in communication and patient engagement, as stigma and biases can a ect the patient-provider relationship. Furthermore, the management of obesity-related comorbidities, such as diabetes and hypertension, complicates gynecological care and necessitates a multidisciplinary approach. Addressing these challenges requires enhanced training for healthcare professionals, the development of tailored treatment plans, and improved patient education to promote weight management and healthy lifestyle choices. By acknowledging and e ectively managing the di culties associated with morbid obesity, gynecological care can be optimized, ultimately improving health outcomes for a ected individuals.

Keywords:

Introduction

( ) 40 1 .

2 .

( )

3 .

4 .

5 ,

Results and Discussion

6 .

( ).

***Corresponding author:** Albert Opal, Department of Food Science and Nutrition, Sultan Qaboos University, Oman, E-mail: albert.ao@opal.com

Received: 01-Oct-2024, Manuscript No. jomb-24-150353; **Editor assigned:** 03-Oct-2024, Pre QC No. jomb-24-150353 (PQ); **Reviewed:** 17-Oct-2024, QC No. jomb-24-150353, **Revised:** 22-Oct-2024, Manuscript No jomb-24-150353 (R); **Published:** 31-Oct-2024, DOI: 10.4172/jomb.1000242

Citation: Albert O (2024) Di culties of Morbid Obesity in Gynaecological Health Management. J Obes Metab 7: 242.

Copyright: © 2024 Albert O. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

[illegible]

10 [illegible]

Conclusion

[illegible]

Acknowledgement

[illegible]

Interest of Con ict

[illegible]

References

1. Dostalova G, Hlubocka Z, Lindner J, Hulkova H, Poupetova H, et al. (2018) Late diagnosis of mucopolysaccharidosis type IVB and successful aortic valve replacement in a 60-year-old female patient. Cardiovasc Pathol 35: 52-56.
2. Hampe CS, Eisengart JB, Lund TC, Orchard PJ, Swietlicka M, et al. (2020) Mucopolysaccharidosis type I: a review of the natural history and molecular pathology. Cells 9: 1838.
3. Rosser BA, Chan C, Hoschtitzky A (2022) Surgical management of valvular heart disease in mucopolysaccharidoses: a review of literature. Biomedicines 10: 375.
4. Walker R, Belani KG, Braunlin EA, Bruce IA, Hack H, et al (2013) Anaesthesia and airway management in mucopolysaccharidosis. J Inherit Metab Dis 36: 211-219.
5. Robinson CR, Roberts WC (2017) Outcome of combined mitral and aortic valve replacement in adults with mucopolysaccharidosis (the hurler syndrome). Am J Cardiol 120: 2113-2118.
6. Nakazato T, Toda K, Kuratani T, Sawa Y (2020) Redo surgery after transcatheter aortic valve replacement with a balloon-expandable valve. JTCVS Tech 3: 72-74.
7. Gorla R, Rubbio AP, Oliva OA, Garatti A, Marco FD, et al. (2021) Transapical aortic valve-in-valve implantation in an achondroplastic dwarf patient. J Cardiovasc Med (Hagerstown) 22: e8-e10.
8. Mori N, Kitahara H, Muramatsu T, Matsuura K, Nakayama T, et al. (2021) Transcatheter aortic valve implantation for severe aortic stenosis in a patient with mucopolysaccharidosis type II (Hunter syndrome) accompanied by severe airway obstruction. J Cardiol Cases 25: 49-51.
9. Gabrielli O, Clarke LA, Bruni S, Coppa GV (2010) Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up. Pediatrics, 125: e183-e187.
10. Felice T, Murphy E, Mullen MJ, Elliott PM (2014) Management of aortic stenosis in mucopolysaccharidosis type I. Int J Cardiol 172: e430-e431.